COMPANY

OnCusp Therapeutics

Keywords: oncology cancer Ovarian Cancer CUSP06

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series A · $100M · announced Jan 4, 2024 Company release ↗
Source quote
- Jan 4, 2024 · Company release ↗
  “OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients”

Raises announced in these releases: $100M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Feb 9, 2024 Trial start Phase 1: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors source ↗
Jan 4, 2024 Raise Series A · $100M source ↗

May 30, 2027 (ESTIMATED) · Phase 1 · A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors · NCT06234423

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06234423	A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors	Phase 1	Recruiting	Feb 9, 2024	May 30, 2027 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗
InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗